WebOct 5, 2024 · Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, an investigational Phase 3 … WebJun 29, 2024 · EMERYVILLE, Calif.-- ( BUSINESS WIRE )--Boston Therapeutics, Inc. (the “Company”) (OTCQB:BTHE) and merger partner Nanomix, Inc. (“Nanomix”), a leader in the development of mobile, affordable,...
Putting Cancer
WebOct 5, 2024 · Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe ... WebTechnology. Bilayer’s lead program, BL-010, is a potential first-in-class therapeutic for chronic constipation co-developed by the Langer and Traverso Labs at the … show laverne and shirley
BTAI Stock Price BioXcel Therapeutics Inc. Stock Quote (U.S.: …
WebNov 29, 2024 · -- Lengo Therapeutics to be acquired for $250 million in cash plus $215 million in future potential payments based on the achievement of certain approval and sales-based milestones WebAbout Reset Therapeutics, a biopharmaceutical company, develops and commercializes products that modulate the circadian system of the human body. South San Francisco, California, United States 11-50 Venture - Series Unknown Private resettherapeutics.com 29,282 Highlights Total Funding Amount $53.6M Contacts 1 Similar Companies 13 WebAbout. Entrepreneurial-spirited, technology leader with over 16+ years of proven experience in biopharma and ivd. Problem-solver with a passion for using innovation effectively to … show lawn mowers